Allergen-specific immunotherapy remains the most likely effective treatment modality for allergic disorders by targeting the underlying immune mechanisms and possibly causing modifications in the disease course, as well as treating the symptoms. Treatment and compliance experiences been gained over nearly a century in injection-type allergen-specific immunotherapy have motivated the development of newer, alternative routes. Adverse events and safety concerns, efficacy and ease of application seem to be the stimulating factors for the development of a sublingual form of this treatment modality, wherein the principal factor is the capture of the antigen (allergen) by dendritic cells, in the location where oral tolerance arises. Due to the presence of high numbers of tolerogenic dendritic cell subsets in this region, programming of the immune system towards a regulatory state with unresponsiveness to specific allergens occurs. Induction of peripheral tolerance through the generation of regulatory T cells is the key event, with several functional modulations in the allergic immune response. With an increase in understanding of the mechanism of regulatory pathways, promising progresses in the field of allergen-specific immunotherapy will ensue and may provide new options for the treatment of allergic disorders.
Abramson, M.J., Puy, R.M. and Weiner, J.M. ( 2003) Allergen immunotherapy for asthma. Cochrane Database Syst Rev: CD001186.
2.
Acquistapace, F., Agostinis, F., Castella, V., Kantar, A., Novembre, E., Perrone, M.R. et al. (2009) Efficacy of sublingual specific immunotherapy in intermittent and persistent allergic rhinitis in children: an observational case-control study on 171 patients. The EFESO-children Multicenter Trial. Pediatr Allergy Immunol Mar23 [Epub ahead of print].
3.
Akdis, C.A. ( 2008) New insights into mechanisms of immunoregulation in 2007 . J Allergy Clin Immunol122: 700-709.
4.
Akdis, C.A. and Akdis, M. ( 2009) Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol123: 735-746, quiz 747-738.
5.
Akdis, C.A., Barlan, I.B., Bahceciler, N. and Akdis, M. ( 2006) Immunological mechanisms of sublingual immunotherapy. Allergy61 Suppl 81: 11-14.
6.
Akdis, C.A., Blesken, T., Akdis, M., Wuthrich, B. and Blaser, K. ( 1998) Role of interleukin 10 in specific immunotherapy. J Clin Invest102: 98-106.
7.
Akdis, M. ( 2006) Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol18: 738-744.
8.
Akdis, M. ( 2008a) Immunologic responses to sublingual allergen immunotherapy . Clin Allergy Immunol21: 71-86.
9.
Akdis, M. ( 2008b) T-cell tolerance to inhaled allergens: mechanisms and therapeutic approaches. Expert Opin Biol Ther8: 769-777.
10.
Akdis, M. and Akdis, C.A. ( 2007) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol119: 780-791.
11.
Akpinarli, A., Tuncer, A., Saraclar, Y., Sekerel, B.E. and Kalayci, O. ( 1999) Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Arch Dis Child81: 45-48.
12.
Allam, J.P., Novak, N., Fuchs, C., Asen, S., Berge, S., Appel, T. et al. (2003) Characterization of dendritic cells from human oral mucosa: a new Langerhans’ cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol112: 141-148.
13.
Allam, J.P., Stojanovski, G., Friedrichs, N., Peng, W., Bieber, T., Wenzel, J. et al. (2008) Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy63: 720-727.
14.
Alpan, O. ( 2001) Oral tolerance and gut-oriented immune response to dietary proteins. Curr Allergy Asthma Rep1: 572-577.
15.
Alpan, O., Rudomen, G. and Matzinger, P. ( 2001) The role of dendritic cells, B cells, and M cells in gut-oriented immune responses. J Immunol166: 4843-4852.
16.
Bagnasco, M., Mariani, G., Passalacqua, G., Motta, C., Bartolomei, M., Falagiani, P. et al. (1997) Absorption and distribution kinetics of the major parietaria judaica allergen (Par J 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol100: 122-129.
17.
Bahceciler, N.N., Ozdemir, C. and Barlan, I.B. ( 2007) Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma. Curr Med Chem14: 265-269.
18.
Bohle, B., Kinaciyan, T., Gerstmayr, M., Radakovics, A., Jahn-Schmid, B. and Ebner, C. ( 2007) Sublingual immunotherapy induces Il-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol120: 707-713.
19.
Bousquet, J., Lockey, R. and Malling, H.J. ( 1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol102: 558-562.
20.
Bousquet, J., Scheinmann, P., Guinnepain, M.T., Perrin-Fayolle, M., Sauvaget, J., Tonnel, A.B. et al. (1999) Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy54: 249-260.
21.
Bousquet, J., Van Cauwenberge, P. and Khaltaev, N. ( 2001) Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol108: S147-334.
22.
Burastero, S.E., Mistrello, G., Falagiani, P., Paolucci, C., Breda, D., Roncarolo, D. et al. (2008) Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-Cell proliferation and interleukin 10 production. Ann Allergy Asthma Immunol100: 343-350.
23.
Burgler, S., Ouaked, N., Bassin, C., Basinski, T.M., Mantel, P.Y., Siegmund, K. et al. (2009) Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol123: 588-595, 595e581-587.
24.
Calamita, Z., Saconato, H., Pela, A.B. and Atallah, A.N. ( 2006) Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method . Allergy61: 1162-1172.
25.
Canonica, G.W. and Passalacqua, G. ( 2006) Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. Allergy61(Suppl. 81): 20-23.
26.
Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N. et al. (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor FoxP3. J Exp Med198: 1875-1886.
27.
Clavel, R., Bousquet, J. and Andre, C. ( 1998) Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy53: 493-498.
28.
Cosmi, L., Santarlasci, V., Angeli, R., Liotta, F., Maggi, L., Frosali, F. et al. (2006) Sublingual immunotherapy with dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy36: 261-272.
29.
Cox, L. ( 2008) Sublingual immunotherapy and allergic rhinitis. Curr Allergy Asthma Rep8: 102-110.
30.
Dardalhon, V., Awasthi, A., Kwon, H., Galileos, G., Gao, W., Sobel, R.A. et al. (2008) Il-4 inhibits TGF-beta-induced FoxP3+ T cells and, together with TGF-beta, generates Il-9+ Il-10+ FoxP3(-) effector T cells . Nat Immunol9: 1347-1355.
31.
Des Roches, A., Paradis, L., Menardo, J.L., Bouges, S., Daures, J.P. and Bousquet, J. ( 1997) Immunotherapy with a standardized dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol99: 450-453.
32.
Di Gioacchino, M., Perrone, A., Petrarca, C., Di Claudio, F., Mistrello, G., Falagiani, P. et al. (2008) Early cytokine modulation after the rapid induction phase of sublingual immunotherapy with mite monomeric allergoids. Int J Immunopathol Pharmacol21: 969-976.
33.
Eberlein-Konig, B., Ullmann, S., Thomas, P. and Przybilla, B. ( 1995) Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization. Clin Exp Allergy25: 704-712.
34.
Estes, D.M., Hirano, A., Heussler, V.T., Dobbelaere, D.A. and Brown, W.C. ( 1995) Expression and biological activities of bovine interleukin 4: Effects of recombinant bovine interleukin 4 on T cell proliferation and B cell differentiation and proliferation in vitro. Cell Immunol163: 268-279.
35.
Fenoglio, D., Puppo, F., Cirillo, I., Vizzaccaro, A., Ferrera, A., Tosca, M.A. et al. (2005) Sublingual specific immunotherapy reduces PBMC proliferations. Eur Ann Allergy Clin Immunol37: 147-151.
36.
Frauwirth, K.A. and Thompson, C.B. ( 2002) Activation and inhibition of lymphocytes by costimulation . J Clin Invest109: 295-299.
37.
Freeman, G.J., Gribben, J.G., Boussiotis, V.A., Ng, J.W., Restivo Jr, V.A., Lombard, L.A. et al. (1993) Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science262: 909-911.
38.
Friedman, A. ( 1996) Induction of anergy in Th1 lymphocytes by oral tolerance. importance of antigen dosage and frequency of feeding. Ann N Y Acad Sci778: 103-110.
39.
Furin, M.J., Norman, P.S., Creticos, P.S., Proud, D., Kagey-Sobotka, A., Lichtenstein, L.M. et al. (1991)
40.
Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol88: 27-32.
41.
Garcia, B.E., Sanz, M.L., Gato, J.J., Fernandez, J. and Oehling, A. ( 1993) IgG4 blocking effect on the release of antigen-specific histamine. J Investig Allergol Clin Immunol3: 26-33.
42.
Gause, W.C., Urban, J.F., Linsley, P. and Lu, P. ( 1995) Role of B7 Signaling in the Differentiation of naive CD4+ T Cells to effector interleukin-4-producing T helper cells. Immunol Res14: 176-188.
43.
Gillis, S., Ferm, M.M., Ou, W. and Smith, K.A. ( 1978) T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol120: 2027-2032.
44.
Huber, S., Schramm, C., Lehr, H.A., Mann, A., Schmitt, S., Becker, C. et al. (2004) Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T Cells. J Immunol173: 6526-6531.
45.
Ippoliti, F., De Santis, W., Volterrani, A., Lenti, L., Canitano, N., Lucarelli, S. et al. (2003) Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol14: 216-221.
46.
Jutel, M. and Akdis, C.A. ( 2008) T-cell regulatory mechanisms in specific immunotherapy . Chem Immunol Allergy94: 158-177.
47.
Jutel, M., Akdis, M., Budak, F., Aebischer-Casaulta, C., Wrzyszcz, M., Blaser, K. et al. (2003) Il-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy . Eur J Immunol33: 1205-1214.
48.
Jutel, M., Muller, U.R., Fricker, M., Rihs, S., Pichler, W.J. and Dahinden, C. ( 1996) Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy26: 1112-1118.
49.
Kapsenberg, M.L. ( 2003) Dendritic-cell control of pathogen-driven T-cell polarization . Nat Rev Immunol3: 984-993.
50.
Kasaian, M.T. and Miller, D.K. ( 2008) Il-13 as a therapeutic target for respiratory disease . Biochem Pharmacol76: 147-155.
51.
Korn, T., Oukka, M., Kuchroo, V. and Bettelli, E. ( 2007) Th17 cells: effector T cells with inflammatory properties . Semin Immunol19: 362-371.
52.
Kuo, C.H., Wang, W.L., Chu, Y.T., Lee, M.S. and Hung, C.H.(2009) Sublingual immunotherapy in children: an updated review. Pediatr Neonatol50: 44-49.
53.
Kussebi, F., Karamloo, F., Rhyner, C., Schmid-Grendelmeier, P., Salagianni, M., Mannhart, C. et al. (2005) A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol115: 323-329.
54.
Larche, M., Akdis, C.A. and Valenta, R. ( 2006) Immunological mechanisms of allergen-specific immunotherapy . Nat Rev Immunol6: 761-771.
55.
Lombardi, C., Incorvaia, C., Braga, M., Senna, G., Canonica, G.W. and Passalacqua, G.(2009) Administration regimens for sublingual immunotherapy to pollen allergens: what do we know?Allergy64: 849-854.
56.
Lotvall, J. ( 2004) Combination therapy in asthma - fixed or variable dosing in different patients? Curr Med Res Opin20: 1711-1727.
57.
Mantel, P.Y., Kuipers, H., Boyman, O., Rhyner, C., Ouaked, N., Ruckert, B. et al. (2007) Gata3-driven Th2 responses inhibit TGF-beta1-induced FoxP3 expression and the formation of regulatory T cells. PLoS Biol5: e329.
58.
Marcucci, F., Incorvaia, C., Sensi, L., Di Cara, G., Cadario, G., Cavaliere, A. et al. (2008) Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol21: 609-613.
59.
Marogna, M., Tomassetti, D., Bernasconi, A., Colombo, F., Massolo, A., Businco, A.D. et al. (2008) Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol101: 206-211.
60.
Mascarell, L., Lombardi, V., Louise, A., Saint-Lu, N., Chabre, H., Moussu, H. et al. (2008) Oral dendritic cells mediate antigen-specific tolerance by stimulating Th1 and regulatory CD4+ T cells. J Allergy Clin Immunol122: 603-609e605.
61.
Meiler, F., Klunker, S., Zimmermann, M., Akdis, C.A. and Akdis, M. ( 2008) Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy63: 1455-1463.
62.
Meiler, F., Zumkehr, J., Klunker, S., Ruckert, B., Akdis, C.A. and Akdis, M. ( 2008) In vivo switch to Il-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med205: 2887-2898.
63.
Moingeon, P., Batard, T., Fadel, R., Frati, F., Sieber, J. and Van Overtvelt, L. ( 2006) Immune mechanisms of allergen-specific sublingual immunotherapy . Allergy61: 151-165.
64.
Moller, C., Dreborg, S., Ferdousi, H.A., Halken, S., Host, A., Jacobsen, L. et al. (2002) Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol109: 251-256.
65.
Mothes, N., Heinzkill, M., Drachenberg, K.J., Sperr, W.R., Krauth, M.T., Majlesi, Y. et al. (2003) Allergen-specific immunotherapy with a monophosphoryl lipid a-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies . Clin Exp Allergy33: 1198-1208.
66.
Muller, U., Helbling, A. and Bischof, M. ( 1989) Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy44: 412-418.
67.
Nelson, H.S. ( 2005) Advances in upper airway diseases and allergen immunotherapy . J Allergy Clin Immunol115: 676-684.
68.
Novembre, E., Galli, E., Landi, F., Caffarelli, C., Pifferi, M., De Marco, E. et al. (2004) Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol114: 851-857.
69.
Ouaked, N., Mantel, P.Y., Bassin, C., Burgler, S., Siegmund, K., Akdis, C.A. et al. (2009) Regulation of the FoxP3 gene by the Th1 cytokines: the role of Il-27-induced STAT1. J Immunol182: 1041-1049.
70.
Ozdemir, C., Akdis, M. and Akdis, C.A.(2009) T regulatory cells and their counterparts: masters of immune regulation . Clin Exp Allergy39: 626-639.
71.
Ozdemir, C., Yazi, D., Gocmen, I., Yesil, O., Aydogan, M., Semic-Jusufagic, A. et al. (2007) Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol18: 508-515.
72.
Pajno, G.B., Caminiti, L., Vita, D., Barberio, G., Salzano, G., Lombardo, F. et al. (2007) Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol120: 164-170.
73.
Passalacqua, G., Albano, M., Fregonese, L., Riccio, A., Pronzato, C., Mela, G.S. et al. (1998) Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis . Lancet351: 629-632.
74.
Passalacqua, G., Albano, M., Riccio, A., Fregonese, L., Puccinelli, P., Parmiani, S. et al. (1999) Clinical and immunologic effects of a rush sublingual immunotherapy to parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol104: 964-968.
75.
Passalacqua, G. and Durham, S.R. ( 2007) Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol119: 881-891.
76.
Passalacqua, G., Guerra, L., Compalati, E. and Canonica, G.W. ( 2007) The safety of allergen specific sublingual immunotherapy . Curr Drug Saf2: 117-123.
77.
Penagos, M., Passalacqua, G., Compalati, E., Baena-Cagnani, C.E., Orozco, S., Pedroza, A. et al. (2008) Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest133: 599-609.
78.
Razafindratsita, A., Saint-Lu, N., Mascarell, L., Berjont, N., Bardon, T., Betbeder, D. et al. (2007) Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol120: 278-285.
79.
Read, S., Malmstrom, V. and Powrie, F. ( 2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med192: 295-302.
80.
Romagnani, S. ( 2004) Immunologic influences on allergy and the Th1/Th2 balance . J Allergy Clin Immunol113: 395-400.
81.
Romani, N., Koide, S., Crowley, M., Witmer-Pack, M., Livingstone, A.M., Fathman, C.G. et al. (1989) Presentation of exogenous protein antigens by dendritic cells to T cell clones. intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med169: 1169-1178.
82.
Rossi, R.E., Monasterolo, G., Coco, G., Silvestro, L. and Operti, D. ( 2007) Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine25: 957-964.
83.
Saint-Lu, N., Tourdot, S., Razafindratsita, A., Mascarell, L., Berjont, N., Chabre, H. et al. (2009) Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy64: 1003-1013.
84.
Sander, I., Fleischer, C., Meurer, U., Bruning, T. and Raulf-Heimsoth, M. ( 2009) Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy Apr 6 [Epub ahead of print].
85.
Savolainen, J., Jacobsen, L. and Valovirta, E. ( 2006) Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy61: 1184-1190.
86.
Sehmi, R., Wardlaw, A.J., Cromwell, O., Kurihara, K., Waltmann, P. and Kay, A.B. ( 1992) Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood79: 2952-2959.
87.
Sennhauser, F.H., Braun-Fahrlander, C. and Wildhaber, J.H. ( 2005) The burden of asthma in children: aEuropean perspective. Paediatr Respir Rev6: 2-7.
88.
Steinman, R.M. and Cohn, Z.A. ( 1973) Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med137: 1142-1162.
89.
Storms, W.W. ( 2004) Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J Allergy Clin Immunol114: S146-153.
90.
Tari, M.G., Mancino, M., Madonna, F., Buzzoni, L. and Parmiani, S. ( 1994) Immunologic evaluation of 24 month course of sublingual immunotherapy. Allergol Immunopathol ( Madr) 22: 209-216.
91.
Till, S.J., Francis, J.N., Nouri-Aria, K. and Durham, S.R. ( 2004) Mechanisms of immuno-therapy. J Allergy Clin Immunol113: 1025-1034, quiz 1035.
92.
Tseng, S.H., Fu, L.S., Nong, B.R., Weng, J.D. and Shyur, S.D. ( 2008) Changes in serum specific IgG4 and IgG4/IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial. Asian Pac J Allergy Immunol26: 105-112.
93.
Van Neerven, R.J., Arvidsson, M., Ipsen, H., Sparholt, S.H., Rak, S. and Wurtzen, P.A. ( 2004) A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy34: 420-428.
94.
Van Neerven, R.J., Wikborg, T., Lund, G., Jacobsen, B., Brinch-Nielsen, A., Arnved, J. et al. (1999) Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol163: 2944-2952.
95.
Van Wijk, R.G. ( 2008) When to initiate immunotherapy in children with allergic disease? Lessons from the paediatric studies. Curr Opin Allergy Clin Immunol8: 565-570.
96.
Veldhoen, M., Uyttenhove, C., Van Snick, J., Helmby, H., Westendorf, A., Buer, J. et al. (2008) Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol9: 1341-1346.
97.
Wills-Karp, M. ( 2004) Interleukin-13 in asthma pathogenesis. Immunol Rev202: 175-190.
98.
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T.Y., Karp, C.L. et al. (1998) Interleukin-13: central mediator of allergic asthma. Science282: 2258-2261.
99.
Wilson, D.R., Irani, A.M., Walker, S.M., Jacobson, M.R., Mackay, I.S., Schwartz, L.B. et al. (2001) Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy31: 1705-1713.
100.
Yoshinaga, S.K., Whoriskey, J.S., Khare, S.D., Sarmiento, U., Guo, J., Horan, T. et al. (1999) T-cell co-stimulation through B7RP-1 and ICOS . Nature402: 827-832.
